Session Description:

IIn this exciting 80-minute session chaired by Dr Julia Mader, the expert faculty will dive into how continuous glucose monitoring (CGM) and once-weekly insulins, treatment and technology united, can address current unmet needs in the management of type 2 diabetes (T2D). Professor Richard Bergenstal will start by discussing evidence and guidelines for use of CGM in clinical trials and day-to-day management of T2D. Dr Mader will introduce once-weekly insulins and present efficacy and safety data and post hoc CGM data from the insulin icodec Phase 2 trials. Finally, Dr Christophe De Block will put the data into clinical context by discussing how CGM and once-weekly insulins can impact future clinical trials, day-to-day clinical practice and patient management. Between plenary sessions, there will be interactive discussions between the experts about future perspectives, such as the insulin icodec Phase 3 programme ONWARDS, and the experts will answer audience questions. The symposium will take place on Thursday 28 April @ 16.40–18.00 CEST.